LifeCycle Pharma Receives US Patent for its MeltDose® Technology

Hørsholm, Denmark, 15 May 2007 LifeCycle Pharma A/S (OMX:LCP) announced today the issuance of a patent for its MeltDose® Technology by the US Patent and Trademark Office, US Patent No. 7,217,431.

The patent covers the method of making a particulate material containing a drug substance with low aqueous solubility, using a unique controlled agglomeration process.

“The issuance of the first US patent for our MeltDose® technology marks a very important step in our efforts to protect the company’s core technology as well as to protect all our product candidates which are based upon our MeltDose® Technology”, said Dr. Flemming Ornskov, President and CEO of LifeCycle Pharma. “This patent provides broad protection and gives us a potential edge over other companies competing in the same area” added Dr. Ornskov.

The issue of the MeltDose® patent does not change the company’s financial expectations for 2007.

About MeltDose Technology:

All of LifeCycle Pharma’s product candidates are based on MeltDose® technology. The company’s MeltDose® technology has been designed to enhance the release and absorption of drugs in the body by incorporating the drug in a solubilized form in a tablet matrix, i.e. as a solid solution. By applying our MeltDose® technology to create new versions of existing drugs, we believe that products can be developed significantly faster and cheaper and with a higher success rate compared with the development required for New Chemical Entities (“NCEs”). This favourable risk/reward profile is a key component of our business strategy.

For further information please contact:

LifeCycle Pharma A/S

Michael Wolff Jensen

Executive Vice President and CFO

Tel. +45 40 74 62 44

---oo0oo---

About LifeCycle Pharma A/S:

LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging pharmaceutical company with a broad and late stage product pipeline in therapeutic areas of cholesterol management, hypertension, organ transplant and autoimmune diseases. LifeCycle Pharma’s product candidates are proprietary and designed to improve the quality of existing drugs by enhancing the release and absorption of drugs in the human body. LifeCycle Pharma’s proprietary technology platform, MeltDose® technology, offers lower dosing, reduced side effects and improved safety and patient compliance, as well as reduced product development time and development costs. LifeCycle Pharma is listed on the OMX Nordic Exchange under the trading symbol (LCP). Please visit www.lcpharma.com for further information about LifeCycle Pharma A/S.